An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
NCT00425854
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
BIBW 2992
Sponsor
Boehringer Ingelheim